Healthcare ETFs Take Different Investment Approaches

Healthcare remains one of the most resilient sectors in the market, supported by aging populations, rising healthcare spending, medical innovation, and demand for new therapies. Investors seeking exposure to the industry can choose between diversified healthcare funds or more specialized pharmaceutical-focused ETFs.

Two popular options are the Health Care Select Sector SPDR Fund (NYSEARCA: XLV) and the iShares U.S. Pharmaceuticals ETF (NYSEARCA: IHE). Although both invest in healthcare-related companies, their investment strategies differ significantly.

XLV Offers Broad Healthcare Diversification

Launched in 1998, XLV provides exposure to approximately 60 large-cap healthcare companies spanning pharmaceuticals, biotechnology, medical devices, healthcare providers, managed care organizations, and life sciences.

Its largest holdings include Eli Lilly, Johnson & Johnson, and AbbVie, which together account for roughly 35% of the portfolio. While these companies have significant influence over fund performance, XLV also benefits from exposure to other healthcare subsectors that can help reduce concentration risk.

The ETF carries an expense ratio of approximately 0.08%, making it one of the lowest-cost healthcare sector funds available. It also offers a dividend yield of around 1.6%, providing an additional source of return for income-focused investors.

IHE Focuses on Pharmaceutical Leaders

The iShares U.S. Pharmaceuticals ETF takes a much narrower approach by investing exclusively in U.S. pharmaceutical companies.

Its portfolio contains roughly 56 holdings, with Johnson & Johnson, Eli Lilly, and Merck representing nearly half of total assets. This concentrated allocation allows investors to benefit more directly from strong pharmaceutical industry performance but also increases company-specific and industry-specific risks.

IHE charges a higher expense ratio of approximately 0.38% and currently offers a dividend yield near 1.48%.

Performance Reflects Concentration

The pharmaceutical sector has recently outperformed much of the broader healthcare industry, helping IHE generate stronger one-year returns than XLV.

This concentrated exposure enables investors to capture greater gains during periods when major drug manufacturers benefit from successful product launches, expanding demand, or favorable pricing conditions.

However, concentration also increases downside risk. Patent expirations, regulatory changes, pricing reforms, clinical trial failures, or disappointing earnings from large pharmaceutical companies could weigh more heavily on IHE than on XLV.

By comparison, XLV’s broader exposure to insurers, medical device manufacturers, diagnostics companies, and healthcare service providers helps reduce reliance on any single healthcare segment.

Cost and Risk Considerations

Lower expenses can significantly improve long-term investment returns, particularly for passive investors holding ETFs over many years.

XLV’s substantially lower management fee provides an advantage for investors focused on minimizing costs while maintaining broad healthcare exposure.

IHE’s higher fee may be justified for investors who have strong conviction that pharmaceutical companies will continue outperforming the broader healthcare sector, but it requires accepting higher volatility and greater concentration risk.

Which ETF May Be the Better Choice?

For investors seeking diversified exposure to one of the market’s most defensive sectors, XLV appears to offer the stronger long-term risk-reward profile. Its broad portfolio, lower expense ratio, and balanced industry exposure make it well suited for buy-and-hold investors.

IHE may appeal to investors with a bullish outlook on pharmaceutical innovation and drug manufacturers, particularly if blockbuster therapies and favorable industry trends continue to drive earnings growth. However, its concentrated portfolio makes it more sensitive to sector-specific challenges.

Outlook

Healthcare continues to benefit from powerful long-term growth drivers, including demographic shifts, medical innovation, and increasing global healthcare demand. Investors choosing between XLV and IHE should consider whether they prefer diversified exposure across the healthcare ecosystem or a higher-conviction investment focused specifically on pharmaceutical companies. For most long-term investors, XLV’s broader diversification and lower costs provide a more balanced approach, while IHE remains an attractive option for those willing to assume greater sector-specific risk in pursuit of potentially higher returns.